In Alzheimer's disease models, icariin ameliorates cognitive deficits by modulating multiple pathways, including BACE-1, NO/cyclic guanosine monophosphate (cGMP), Wnt/Ca2+, and PI3K/Akt signaling. This evidence concerns the gene AKT1 and early-onset autosomal dominant Alzheimer disease.